EP12: What can we learn from the FDA model by AI Now Institute

Disclaimer: This podcast is completely AI generated by ⁠⁠⁠NoteBookLM⁠⁠⁠ 🤖 Summary During this episode we discuss this document that explores the potential for applying lessons from the US Food and Drug Administration (FDA) to the regulation of artificial intelligence (AI). It examines 10 key insights from a discussion amongst experts in AI, pharmaceuticals, and the FDA. The document argues that a direct “FDA for AI” approach is too simplistic and that a more nuanced approach is needed, focusing on different parts of the AI supply chain. The document suggests that lessons from the FDA’s information-production function, which has led to greater transparency in the pharmaceutical industry, could be applied to AI. It also highlights the importance of evaluating not just the safety but also the efficacy of AI systems, requiring developers to demonstrate the benefits they provide. The document concludes that greater transparency and documentation requirements are essential to improve accountability within the AI sector.

There are no comments yet.

Please log in to write the first comment.